Our observations also highlight the need to integrate specific questions about potential recent TB exposure and new risk factors for TB (e.g., travel to high TB prevalence region) into regular clinical reviews while patients are receiving anti-TNF-α agents, considering that one of the study participants who developed TB disease had known TB exposure. This evidence concerns the gene TNF and tuberculosis.